Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Intangibles: 2011-2022

Historic Intangibles for Abeona Therapeutics (ABEO) over the last 10 years, with Sep 2022 value amounting to $2.2 million.

  • Abeona Therapeutics' Intangibles changed negligibly% to $2.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $2.2 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.2 million for FY2021, which is negligibly% changed negligibly from last year.
  • Per Abeona Therapeutics' latest filing, its Intangibles stood at $2.2 million for Q3 2022, which was down 0.00% from $2.2 million recorded in Q2 2022.
  • Over the past 5 years, Abeona Therapeutics' Intangibles peaked at $44.9 million during Q4 2018, and registered a low of $2.2 million during Q4 2020.
  • Over the past 3 years, Abeona Therapeutics' median Intangibles value was $2.2 million (recorded in 2022), while the average stood at $2.3 million.
  • In the last 5 years, Abeona Therapeutics' Intangibles surged by 1,046.25% in 2019 and then slumped by 93.88% in 2020.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Intangibles stood at $44.9 million in 2018, then soared by 1,046.25% to $42.6 million in 2019, then crashed by 93.88% to $2.2 million in 2020, then remained steady at $2.2 million in 2021, then remained steady at $2.2 million in 2022.
  • Its Intangibles stands at $2.2 million for Q3 2022, versus $2.2 million for Q2 2022 and $2.2 million for Q1 2022.